Syros Pharmaceuticals, Inc. (SYRS) earnings
SYRS earnings moved a median of -0.40% by the close. Quarterly and annual SYRS reports and results, each read against the price at its own news timestamp. Back to the SYRS overview →
13 measured SYRS earnings events.
Where these SYRS earnings landedvs 13 measured SYRS earnings reactions
| Middle 50% of SYRS earnings reactions | -4.92% to +6.05% |
|---|---|
| Median reaction (to close) | -0.40% |
| Measured reactions | 13 |
Point-in-time · zero look-ahead
Half of the 13 SYRS earnings events with a measured close landed between -4.92% and +6.05%; 46% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Syros Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -1.19% | -0.40% | |
| Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update | Press release | -1.19% | -0.40% | |
| Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 | Press release | +2.88% | -8.41% | |
| Form 10-Q Syros Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.77% | -7.55% | |
| Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | -0.77% | -7.55% | |
| Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 | Press release | +0.00% | -4.92% | |
| Form 10-Q Syros Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +3.52% | +6.05% | |
| Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update | Press release | +3.52% | +6.05% | |
| Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 | Press release | +0.00% | +1.78% | |
| Form 10-K Syros Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -5.59% | -1.85% | |
| Form 10-Q Syros Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.79% | +6.67% | |
| Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update | Press release | +0.79% | +6.67% | |
| Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 | Press release | +1.17% | +4.61% |
Keep exploring
More SYRS: analyst actions → · SEC filings → · SYRS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | 309 | 0.00% | 50% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.